drugset / Trial / NCT04920370
Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
RandomizedSequentialDouble-blindTreatment
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1720 administered subcutaneously (SC) or intravenously (IV).
Timeline
- Start
- 2019-09-04
- Primary completion
- 2021-11-16
- Completion
- 2021-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefurulimab | Monoclonal antibody | — | Subcutaneous |
| Subject | rHuPH20 | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.